Skip to main content

Case Reports in Hematological Malignancies : 2022

150kviews
Editorial21 August 2023
Editorial: Case reports in hematological malignancies: 2022

the effective concentration range at 7 and 14 days of treatment and maintained remission with manageable side effects. This case highlights the importance of drug-food interaction combinations in reducing the dose and cost of venetoclax, especially in low to middle-income countries. A case of concurrent Langerhans cell histiocytosis (LCH) and AML which shared driver mutations in an 84-year-old female patient was reported by Kazama et al. The diagnosis was based on biopsy where LCH was primarily identified in the skin, lymph nodes, and bone marrow, while AML was predominantly present in the bone marrow and peripheral blood.Only a few numbers of cases of LCH and AML diagnosis at the same time have been reported, the majority of which included generalized LCH, and monocytic leukemia, and was associated with dismal prognosis (4,5). In summary, this case is in favor of classifying LCH and other forms of histiocytosis as myeloid/myeloproliferative malignancies.Two cases of invasive fungal infection in AML patients were reported. Tabak et al described a case of AML with lungs and sinuses mucormycosis at diagnosis and who had a loss of function mutation in the TNFRSF13B gene. This mutation increases the likelihood of developing immunodeficiency syndromes since it has been demonstrated to impair B-cell differentiation and homeostasis (6). These data highlight the importance of next-generation sequencing for the prognosis and treatment of AML. The other case was a patient with myeloid sarcoma in her right breast who, while receiving the first consolidation course of chemotherapy, acquired a severe fungal infection caused by Saprochaete clavata. The patient was refractory to maximum antifungal therapy and the treatment was successful only when granulocyte transfusion therapy was initiated. In this case, Pasqualone et al suggest the addition of granulocyte transfusions as adjunctive therapy for patients with profound and long-lasting neutropenia and severe fungal infections resistant to broad-spectrum antimicrobial treatment (7).Interestingly, three cases of atypical acute promyelocytic leukemia (APL) were presented in this collection.Zhao et al reported a case of AML with Retinoic acid receptor gamma gene rearrangement which resembled classical APL in clinical features, morphology, and immunophenotype but did not carry the diagnostic PML-RARA fusion gene (8). This APL-like case showed resistance to all-trans retinoic acid (ATRA) and Arsenic trioxide but responded well to homoharringtonine and cytarabine. The second case reported by Chen et al was a variant APL with BCOR-RARA instead of PML-RARA fusion gene. The patient was successfully treated by ATRA plus standard chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) and ATRA maintenance and maintained molecular remission. Variant APL cases have a high risk of relapse which warrants accurate identification and optimal aggressive therapy (9).The third case reported by Chen et al was an APL-like case in a 3-year-old child caused by torque teno mini virus (TTMV) fragment integration into the RARA locus which suggests that TTMV: RARA is a recurrent cause of APL missing PML: RARA. Only two similar APL-like cases caused by TTMV integration were reported in the literature (10,11). This case highlights the identification of more TTMV: RARA positive APL-like cases considering the widespread prevalence of TTMV in the general population.Two reports of stem-cell transplantation in AML patients were included in this collection. Zheng et al reported the first 2 cases in the literature of successful haploidentical allo-HSCT in AML patients from donors having mild alpha(a)-thalassemia. Follow-up on these 2 patients showed a full donor chimerism, no development of chronic GVHD, and both experienced conversion to donors' thalassemia type with mild microcytic anemia and maintaining Hb levels between 10 to 12 g/dL without transfusion.Wang et al reported a case of Gastrointestinal-GVHD in an AML young female after allo-HSCT that was complicated by small bowel obstruction. The patient experienced prolonged bloody diarrhea after stopping cyclosporine and the gradual reduction in steroids. Imaging showed intestinal stricture 10 months after the transplant. She was treated successfully with surgical resection of the small intestinal stenotic loop after the failure of appropriate immunosuppressive therapies.The last two case reports in the acute leukemia set were two cases of acute lymphoblastic leukemia (ALL).Ni et al reported a case of Donor-derived leukemia (DDL) in a patient who was initially diagnosed with Bcell ALL, for which she received induction chemotherapy then she received salvage chemotherapy after relapse. Last she underwent umbilical cord blood transplantation (UCBT) after the first relapse and achieved CR2.Unfortunately, the patient had a disease relapse again after UCBT. Interestingly, the result of chimerism still showed complete donor chimerism which is consistent with DDL. DDL is an uncommon but serious complication after transplant (12). DDL after UCBT is usually resistant to chemotherapy and the prognosis is very dismal (13). The patient was resistant to chemotherapy, however, she received anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell therapy and achieved CR with negative minimal residual disease (MRD). Then she received preemptive interferon-a treatment after the rise of MRD levels and maintained CR for 41 months. Interferon-a enhances the graft-versus-leukemia effect and is used as an adjuvant or maintenance therapy after transplant to eliminate MRD and lower the risk of leukemia recurrence (14). This study offers a novel therapeutic strategy for DDL.The second case reported by Wang et al was a child with B-cell ALL carrying the rare mutation TP53 c.C275T. This mutation is very rare and is associated with poor prognosis (15). The patient showed resistance to most conventional chemotherapy regimens. In vitro, drug sensitivity tests have shown that bortezomib had a very strong susceptibility to the patient's leukemic cells. Therefore, the patient was then treated with bortezomib in combination with vindesine, fludarabine, and cytarabine. She achieved MRDnegative CR after one course of therapy and continued recurrence-free after a 9-month. According to this report, bortezomib in combination with chemotherapy may be an effective therapy for ALL patients carrying TP53 c.C275T mutation.Cases of chronic leukemias are well represented in this collection. Ramdohr et al reported 2 patients with atypical chronic myeloid leukemia (CML) carrying the BCR: ABL1 e6a2 fusion transcript. Most CML patients are diagnosed with the e13a2 or e14a2 BCR: ABL1 fusion transcripts. However, there is a growing number of CML cases with atypical clinical presentations that are associated with other transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3, and e6a2. These transcripts have been described in 1% of CML patients and their clinical significance is yet to be determined (16)(17)(18). For example, the atypical e6a2 BCR: ABL1 transcript seems to portend poor prognosis as it is associated with an aggressive phenotype and early transformation into acute leukemia (19). The reported 2 patients expressing the atypical e6a2 BCR: ABL1 fusion transcript were treated effectively with the 2 nd generation tyrosine kinase inhibitor, nilotinib. The second article on CML was reported by Pasquale et al. The patient developed severe pleural effusion secondary to nilotinib therapy and was managed with steroids and permanent withdrawal of the medication.Pleural effusion is a well-known toxicity related to dasatinib, which has been linked to either the expansion of cytotoxic T and NK cells or the activation of additional kinases (20). But it's extremely rare during nilotinib therapy, especially in first-line settings.Bi et al described the first case of the coexistence of primary pulmonary lymphoma and opportunistic pneumonia in a patient with CML on imatinib therapy. Primary pulmonary lymphoma is a rare neoplasm and has very nonspecific clinical features that can overlap with infection and often cause delay or neglect in diagnosis (21). This patient continued to have lung disease progression even after optimal antimicrobial coverage. The lymphoma was then diagnosed by CT-guided biopsy, and he received chemotherapy and is still alive at the date of report writing.Vermeersch et al reported a case series (n=5) of chronic neutrophilic leukemia (CNL) associated with monoclonal gammopathy. They analyzed the genetic characteristics of these cases using cytogenetic and molecular studies. CNL is a rare type of BCR: ABL1 negative MPN, defined by persistent mature neutrophilia and hypercellular bone marrow (22). CSF3R mutation is found in up to 80% of CNLs. CNL is associated with plasma cell neoplasms in approximately 32% of cases, wherein CSF3R mutation tends to be less frequent (23,24). In this series, 3 patients have shown a predominant lambda light chain expression.Four patients progressed into plasma cell myeloma. All patients received treatment for the associated malignancies such as AML and multiple myeloma (MM), and among these two patients underwent allo-HSCT.Two manuscripts reported cases of chronic lymphocytic leukemia (CLL). The first one by Valvano et al described a very rare association of CLL with hairy cell leukemia (HCL) with the challenges in diagnosis using multicolor flow cytometry and PCR (25). The patient was initially treated with cladribine and rituximab. The other report by Ballotta et al described 2 cases of CLL with post-COVID-19 condition. Both patients had persistent SARS-CoV-2 infection without seroconversion for 7-8 months. The patients were effectively treated with monoclonal antibodies casirivimab/imdevimab infusion. This data highlights the effectiveness of monoclonal antibodies in immunocompromised patients with persistent SARS-CoV-2 infection (26).The topic of lymphomas with rare presentation has been covered in 10 articles. Among them, 3 reports presented the unusual association of lymphoma with other neoplasms. A case of concurrent diffuse large B-cell lymphoma (DLBCL), rectal adenocarcinoma, and hepatocellular carcinoma was reported by Qiu et al. He was successfully treated with six cycles R-GEMOX followed by six cycles R-CHOP to achieve CR for DLBCL. During this course of therapy, the patient received a PD-1 inhibitor (Sintilimab) as a treatment for HCC and, ultimately, he ended up with curative intent right hemihepatectomy and Dixon surgery. The second case reported by Bhakta et al described an elderly man with untreated prostate cancer who presented with left thigh pain and eventually developed a pathologic fracture. After fixation surgery, the pathology came out as DLBCL. Staging by PET scan FDG revealed no evidence of disease outside the thigh. The patient was then diagnosed with primary bone lymphoma (PBL) and was treated with chemotherapy Rmini-CHOP protocol. PBL represents less than 5% of all primary bone malignancies and less than 1% of all lymphomas (27). Pathologic fracture is an unusual complication of PBL (28). The authors highlight the importance of suspecting PBL in patients with pathologic fractures. The third case was reported by Accorsi Buttini et al who described the development of high-risk MDS following CAR T-cell therapy in a patient with relapsed refractory DLBCL. Prolonged pancytopenia after CAR T-cell therapy is most likely related to active inflammation milieu together with the impact of previous cytoreductive chemotherapy (29). Bone marrow biopsy showed deletion of chromosome 7 and acquisition of RUNX1 mutation. The authors concluded that the development of MDS could be related to previous chemotherapy, however, impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion could play a role too. Two case reports of lymphoma with unusual site involvement were described in this collection. Johnson et al reported a case of classic HCL with CNS involvement at relapse. The patient was initially treated with cladribine, pentostatin, and rituximab with long-lasting response till he developed CNS disease. Most classic HCL harboring BRAF V600E mutation offers a targeted therapy for the pretreated population (30). This patient achieved CR of relapsed HCL with CNS involvement after treatment with a BRAF inhibitor (Vemurafenib). Yang et al reported a case of relapsed/refractory DLBCL with cardiac involvement. The patient developed cardiac metastasis after 12 months of treatment by conventional first-line chemotherapy and anti-CD19 CAR T cell immunotherapy. Secondary cardiac lymphoma is a rare disease and is associated with a high mortality rate (31). The patient was then treated with salvage chemotherapy, followed by CAR-NK cell immunotherapy and allo-HSCT. Unfortunately, he died of severe pneumonia. This report highlights the significance of early diagnosis and timely treatment to improve the prognosis of secondary cardiac lymphoma.Two articles on Burkitt Lymphoma (BL) and CAR T-cell therapy have been presented in this collection.Ye et al reported a 61-year-old patient with high-risk relapsed-refractory BL who was treated successfully by salvage auto-HSCT followed by CAR T-cell consolidation therapy. The authors highlight the safety and feasibility of CAR T-cell therapy for older high-risk BL patients. The patient is still in CR after 4 years of treatment. The second case, by Wang et al, is a young patient who developed cognitive impairment after CAR T-cell salvage therapy for BL. Neurotoxicity, including cognitive impairment, is a well-known adverse event of CAR-T cell infusion and is associated with a poor outcome (32). The main mechanism of neurotoxicity is neuroinflammation secondary to cytokine release syndrome and effector cell-associated neurotoxicity syndrome (33). Currently, CAR-T therapy-related cognitive impairment has no effective treatment. Sodium oligomannate is an effective treatment for cognitive deficits in mild-to-moderate Alzheimer's dementia through inhibition of neuroinflammation (34). The patient was treated with sodium oligomannate with rivastigmine and had significant improvement in cognitive function.Sun et al reported a case of lymphoma-associated hemophagocytic lymphohistiocytosis complicated by acute necrotizing encephalopathy. This complication is related to cytokine storm. Brain insult secondary to this disease is not uncommon, however, the association with acute necrotizing encephalopathy is rarely reported (35). The patient was successfully treated with chemotherapy, immunoglobulin, and early initiation of steroids.One case of lymphoma with pathologic challenges was reported by Zhang et al. The patient was diagnosed with AITL, or Angioimmunoblastic T-cell lymphoma. AITL is always presented with immense follicular dendritic cell meshwork (36). In this case, the proliferation of spindle cells was so profuse that was easily misdiagnosed as follicular dendritic cells sarcoma. Immunochemical and molecular examinations were consistent with AITL.The last article about lymphoma was reported by Xing et al. The patient was diagnosed with double expression (MYC and BCL2) DLBCL with mutations of ATM and CD58 genes. She received 4 cycles of R-CHOP plus zanubrutinib and achieved only a partial response. An in-vitro high-throughput drug screening using a panel of 117 compounds was applied and showed sensitivity to single-agent bortezomib, thalidomide, and gemcitabine, and to the combination of bortezomib, thalidomide, and dexamethasone (VTD). The patient achieved CR after 2 cycles of VTD followed by 2 cycles of VTD-gemcitabine.Moving to plasma cell neoplasm case reports, Bonometti et al reported a case of small bowel obstruction secondary to plasma cell myeloma (PCM). GI involvement by PCM is extremely rare (37). The patient presented with abdominal pain and signs of small bowel obstruction by CT scan abdomen, for which he underwent urgent ileal resection. Histopathology revealed PCM. Subsequent investigations found serum monoclonal gammopathy, osteolytic bony lesions, and clonal bone marrow plasma cell infiltrate. He was treated with myeloma protocol. The authors emphasize the importance of prompt diagnosis and management of rare GI presentation of PCM. Another case of rare extramedullary disease of myeloma was reported by Li et al. They presented a patient with isolated CNS relapse 7 years after being treated for myeloma by induction therapy followed by auto-HSCT. CNS involvement is very rare, it occurs in only about 1% of patients (38). Isolated CNS relapse is even rarer with only a few case reports, these patients have a very poor prognosis (39). The patient was treated successfully with high-dose methotrexate and lenalidomide. Otsuka-Kamakura et al reported a case of plasmablastic neoplasm with multinucleated giant cells that were difficult to distinguish from plasmablastic lymphoma or PCM of plasmablastic type. Both multinucleated giant cells and mononuclear cells had the same profile, according to IHC and FISH analyses.The authors concluded that the multinucleated giant cells were compatible with cancer stem cells.The last three published articles in this collection presented rare hematological diseases. Yoshida et al reported a case of Rosai-Dorfman disease (RDD) with simultaneous multiple extranodal lesions in the skin, heart, liver, and pelvis. The patient has no cervical lymphadenopathy. She was successfully treated with steroids. RDD is a non-Langerhans cell histiocytosis characterized by fever and bilateral cervical lymphadenopathy. It's commonly presented with extranodal site lesions in the skin, bones, head and neck, kidneys, and CNS (40). The simultaneous cardiac and pelvis involvement has not been reported. This case highlights the atypical distribution of uncommon extranodal lesions of RDD and the need to avoid delays in diagnosis and treatment. Xu et al reported three cases of TEMPI syndrome. TEMPI syndrome is a novel and ultra-rare disease characterized by Monoclonal gammopathy, Erythrocytosis, Telangiectasis, Perinephric fluids collection, and Intrapulmonary shunting (41). Only 29 cases were reported worldwide (42). The patients showed various responses to Myeloma-directed therapy. The response to therapy was assessed by measuring hemoglobin, erythropoietin, and M protein levels throughout the course of treatment.Zhao et al reported 2 cases of HLH, the first one was secondary to NK T-cell lymphoma and the second one was associated with missense variants in the perforin 1 gene. Both cases responded rapidly to ruxolitinib plus dexamethasone protocol without obvious adverse effects. The primary first-line treatment for HLH is chemotherapy-containing regimens. However, some patients are resistant to treatment or unfit for intensive chemotherapy (43,44). This report highlights the importance of ruxolitinib plus dexamethasone as a potential treatment for HLH.In summary, the thirty-three articles published on this Research Topic provide clinical practitioners and researchers valuable insights into diagnosing and treating diseases with unusual presentation and open the door for future research.

2,781 views

CASE REPORT
16 March 2023
Pathological fracture due to primary bone lymphoma in a patient with a history of prostate cancer: A case report and review of literature
Pooja Bhakta, 11 more and Kirill A. Lyapichev

4,419 views

2 citations

CASE REPORT
30 January 2023
Relapsed/refractory diffuse large B cell lymphoma with cardiac involvement: A case report and literature review
Yuanyuan Yang, 3 more and Mingxia Shi
Relapsed/refractory diffuse large B cell lymphoma with cardiac involvement: A case report and literature review
Background: Hematological malignancies of the heart (CHMs) are extremely rare, and include leukemia, lymphoma infiltration, and multiple myeloma with extramedullary manifestations. Cardiac lymphoma can be divided into primary cardiac lymphoma (PCL) and secondary cardiac lymphoma (SCL). Compared to PCL, SCL is relatively more common. Histologically, the most frequent SCL is diffuse large B-cell lymphoma (DLBCL). The prognosis of lymphoma in patients with cardiac involvement is extremely poor. CAR T-cell immunotherapy has been recently become a highly effective treatment for relapsed or refractory diffuse large B-cell lymphoma. To date, there are no guidelines that provide a clear consensus on the management of patients with secondary heart or pericardial involvement. We report a case of relapsed/refractory DLBCL that secondarily affected the heart. Case presentation: A male patient was diagnosed with double-expressor DLBCL based on biopsies of mediastinal and peripancreatic masses and fluorescence in situ hybridization. The patient received first-line chemotherapy and anti-CD19 CAR T cell immunotherapy, but developed heart metastases after 12 months. Considering his physical condition and economic situation of the patient, two cycles of multiline chemotherapies were administered, followed by CAR-NK cell immunotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) at another hospital. After achieving a six-month survival, the patient died of severe pneumonia. Conclusion: The response of our patient emphasizes the importance of early diagnosis and timely treatment to improve the prognosis of SCL and serves as an important reference for SCL treatment strategies.

5,369 views

13 citations

CASE REPORT
31 January 2023
Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
Runan Wang, 11 more and Liangchun Hao

4,133 views

2 citations

High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review
CASE REPORT
20 January 2023
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review
Eugenia Accorsi Buttini, 15 more and Domenico Russo

6,560 views

15 citations

Hairy cell leukemia (HCL) is a rare mature B-cell lymphoproliferative disorder and most often presents as classic hairy cell leukemia. This entity is characterized by indolent course and presence of BRAF V600E mutation. We report the case of an 80-year-old male with history of classical hairy cell leukemia who presented with fatigue, dizziness, shortness of breath, blurring of vision and headache. His initial diagnosis was nine years prior and received treatments with cladribine, pentostatin, and rituximab. Workup showed elevated white blood cell count with atypical lymphocytes, anemia and thrombocytopenia. Peripheral blood smear confirmed HCL relapse and MRI brain showed diffuse non-enhancing masses in the supratentorial and infratentorial regions of the brain. He was initiated on treatment with vemurafenib with improvement in white blood cell count and recovery of platelet count and hemoglobin. Repeat MRI brain after 3 months showed complete resolution of brain lesions. Vemurafenib was discontinued after 6 months with bone marrow biopsy showing no evidence of residual hairy cell leukemia. There has only been limited reports of HCL involvement of central nervous system in the literature. Due to the rarity of the condition, it is not clear which treatments can be effective in intracranial disease control. Our report shows the successful use of vemurafenib resulting in complete remission of relapsed HCL with CNS involvement.

4,985 views

8 citations

CASE REPORT
18 January 2023
Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test
Lijie Xing, 3 more and Zengjun Li

3,632 views

2 citations

Torque teno mini virus driven childhood acute promyelocytic leukemia: The third case report and sequence analysis
CASE REPORT
15 December 2022
Torque teno mini virus driven childhood acute promyelocytic leukemia: The third case report and sequence analysis
Xue Chen, 14 more and Hongxing Liu
In this manuscript, we report torque teno mini virus (TTMV) as a cause of acute promyelocytic leukemia (APL) lacking PML::RARA in a 3-year-old boy. Astolfi et al. firstly identified partial integration of the TTMV genome into RARA intron 2, which resulted in in-frame TTMV::RARA fusion in two APL-like pediatric cases without PML::RARA in November 2021. This fascinating report identified an unexpected exogenous genetic cause of APL and could be of great importance for diagnosing and managing APL. Here we report the third childhood APL-like case caused by TTMV integration and investigate the location and structure of the integrated TTMV sequence. These findings suggest TTMV::RARA is a recurrent cause of APL lacking PML::RARA. Considering the widespread prevalence of TTMV in the population, more TTMV::RARA positive APL-like cases might remain to be identified. Establishing a bioinformatic analysis strategy optimized for the highly variable TTMV genome sequence may facilitate the identification of TTMV::RARA by whole transcript sequencing. An effective PCR protocol to identify TTMV::RARA based on a profound analysis of the conservation of TTMV segments in the fusion transcript is also expected. Also, further investigation is needed to elucidate the oncogenic mechanisms of TTMV integration and the clinical features of TTMV::RARA positive patients.

2,991 views

25 citations

CASE REPORT
4 January 2023
Case report: Rosai-Dorfman disease with rare extranodal lesions in the pelvis, heart, liver and skin
Misaki Yoshida, 8 more and Mitsuhiro Kawano

2,844 views

5 citations

CASE REPORT
21 December 2022
A case report of synchronous triple primary malignancies: Diffuse large B-cell lymphoma, rectal adenocarcinoma and hepatocellular carcinoma
Beixuan Qiu, 2 more and Yifei Li

3,133 views

2 citations

CASE REPORT
5 December 2022
Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association
Luciana Valvano, 7 more and Daniela Lamorte

2,543 views

1 citations

CASE REPORT
8 December 2022
Case report: First report of haploidentical allogeneic hematopoietic stem cell transplantation from donors with mild alpha-thalassemia for acute leukemia
Wenshuai Zheng, 6 more and Hongmei Ning

1,939 views

Multiple myeloma with isolated central nervous system relapse after autologous stem cell transplantation: A case report and review of the literature
Patients with multiple myeloma (MM) rarely present with central nervous system (CNS) involvement as a manifestation of extramedullary disease (EMD), a condition that is associated with poor prognosis. CNS relapse without evidence of systemic involvement is even rarer, and there is no standardized treatment because there are only few case reports. We present a 47-year-old female who was diagnosed with nonsecretory multiple myeloma (NSMM) 9 years previously. She had a complete remission after receiving aggressive therapies, including high-dose chemotherapy and autologous stem cell transplantation (ASCT). However, after 7 years of progression-free survival, she had CNS relapse without evidence of systemic involvement. We switched to a salvage regimen consisting of high-dose methotrexate with lenalidomide. She achieved rapid clinical improvement, with a reduction in cerebrospinal fluid plasmacytosis of more than 80%, and no notable side effects. Our description of this unique case of a patient with MM and isolated CNS relapse after ASCT provides a reference for physicians to provide more appropriate management of these patients. We also reviewed previously reported cases and summarized the outcomes of isolated CNS relapse after ASCT, and discuss the pathogenesis and possible treatment strategies for MM with isolated CNS relapse.

3,556 views

9 citations

CASE REPORT
29 November 2022
Case report: Plasmablastic neoplasm with multinucleated giant cells—Analysis of stemness of the neoplastic multinucleated giant cells
Narumi Otsuka-Kamakura, 3 more and Nobuyuki Hiruta

3,061 views

2 citations

CASE REPORT
24 November 2022
Anti-CD19 chimeric antigen receptor T-cell followed by interferon−α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report
Jing Ni, 8 more and Jian Ge

2,004 views

CASE REPORT
24 October 2022
CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
Mingyu Ye, 4 more and Jianmin Yang

2,698 views

4 citations